Looking Into ARS Pharmaceuticals's Recent Short Interest
Portfolio Pulse from Benzinga Insights
ARS Pharmaceuticals (NYSE:SPRY) has seen a 13.47% increase in short interest, with 19.29% of its float sold short. This is higher than its peers' average of 11.82%. The high short interest could indicate bearish sentiment, but it doesn't guarantee a price drop.
August 19, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ARS Pharmaceuticals has experienced a significant increase in short interest, now at 19.29% of its float, which is higher than its peers. This suggests bearish sentiment but doesn't ensure a price decline.
The increase in short interest to 19.29% of float, which is above the peer average, suggests that investors are bearish on ARS Pharmaceuticals. This could lead to downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100